

Original article

Difference in presentation, outcomes, and hospital epidemiologic trend of COVID-19 among first, second, and third waves in Dhaka Medical College

Authors:

1. **Dr. Reaz Mahmud FCPS, MD**, Assistant Professor, Department of Neurology, Dhaka Medical College. Dhaka, Bangladesh. Phone-+8801912270803. [E-mail-reazdmc22@yahoo.com](mailto:reazdmc22@yahoo.com) and rmahmudneuro@dmc.gov.bd. ORCID ID-0000-0002-9427-1746.
2. **Dr. Md. Ashikul Islam, MD**, Indoor Medical Officer, National Institute of neurosciences and Hospital. Dhaka, Bangladesh. phone: 01737104013, [mail-ashikdmc62@gmail.com](mailto:ashikdmc62@gmail.com), ORCID ID -0000-0001-8331-1362
3. **Dr. Md. Emdadul Haque, MD**, Medical officer, Department of Neurology, Dhaka Medical College. Dhaka, Bangladesh. phone: 0714560256, [mail-dr.emdadmithu@gmail.com](mailto:dr.emdadmithu@gmail.com), ORCID ID 0000-0001-6870-6075
4. **Dr. Md. Dewan Azmal Hussain**, Assistant professor, National Institute of Chest diseases and Hospital, Phone: +8801819449812, Mail: azmal.dr@gmail.com
5. **Dr. Mohammad Rafiqul Islam**, Associate professor, Department of Medicine, shaheed Suhrawardy Medical college. Phone-+8801624413595, Mail: drdrafiq73@yahoo.com.
6. **Dr. Farhana Binte Monayem, MBBS**, Medical officer, Sarkari karmachari Hospital. Dhaka, Bangladesh. Phone-+8801920155971. Mail-farhanabintemonayem@gmail.com. ORCID ID-0000-0001-5023-0638.
7. **Dr. Mostofa Kamal, MD**, Assistant professor, Department of Medicine, Dhaka Medical College. Phone-+8801711582960, mail- mkamal052@gmail.com

8. **Dr. Hashmi Sina MRCP, MD**, Assistant professor, Department of Neurology, Dhaka Medical College. Dhaka, Bangladesh. Phone-+88017189675269, E-mail: hashmi.sina49@gmail.com
9. **Dr. Mohammad Fakhrul Islam, MD**, Assistant professor, Department of Neurology, Dhaka Medical College. Dhaka, Bangladesh. Phone-+88001937859810, mail- fakhruislam.work@gmail.com.
10. **Dr. Ponkaj Kanti Datta**, Assistant professor, Department of Medicine, Dhaka Medical College, Dhaka, Bangladesh. Phone number: +8801711069701. Mail- ponkajdatta@yahoo.com. ORCID ID: [0000-0002-4508-4549](https://orcid.org/0000-0002-4508-4549)
11. **Dr. S.K. Jakaria Been Sayeed, MRCP**, Indoor Medical Officer, National Institute of neurosciences and Hospital. Dhaka, Bangladesh Phone- +8801783335147. Mail- skjakaria1@gmail.com. ORCID ID-0000-0003-1173-4248.
12. **Dr. Sabbir Ahmed Dhali, MD**, Registrar, Department of Neurology, Dhaka Medical College. Dhaka, Bangladesh. Phone-+8801720015583. Mail-dr.sabbirdhali@gmail.com.
13. **Dr. Khairul Islam, FCPS**. Junior consultant, Department of Medicine, Dhaka Medical College, Dhaka, Bangladesh. phone-+8801717696207. Mail- khairul0696207@gmail.com, ORCHID: 00 00000188716270.
14. **Dr. Rifat Hossain Ratul**, Medical Officer, COVID-19 post-acute care and follow-up clinic, Dhaka Medical College. Phone:01631907154, Mail: dr.ratulrifat@gmail.com.
15. **Dr. SK Md. Rubaed Hossain**, Research Assistant, Stroke registry, Department of Neurology, Dhaka Medical College. Dhaka, Bangladesh, Phone: 01680888637, Mail: dr.rubaed94@gmail.com.

16. **Habib Naziat Prince**, MSC, Research Assistant, North South University, **phone:** +8801647237397. Mail- habib.52statru@gmail.com

17. **Dr. Ahmed Hossain Chowdhury**, MD, Associate Professor, Department of Neurology, Dhaka Medical College. Dhaka, Bangladesh. Cell no: +88001712257206. [Mail: ahmedssmc17@yahoo.com](mailto:ahmedssmc17@yahoo.com).

18. **Dr. Kazi Gias Uddin Ahmed**, Associate Professor and Head, Department of Neurology, Dhaka Medical College. Dhaka, Bangladesh. Phone-01611272277 mail- kazi17k43@gmail.com. [ORCID ID-0000-0002-0163-8271](https://orcid.org/0000-0002-0163-8271)

19. **Dr. Md.Titu Miah**, Principal and Professor of Medicine, Department of Medicine, Dhaka Medical College, Dhaka, Bangladesh. **Mobile:** +8801711591770. Mail: titum21@gmail.com

20. **Dr. Md. Mujibur Rahman FCPS, MD, FACP** Professor, Department of Medicine, Bangabandhu Sheikh Mujib Medical University, Dhaka. Bangladesh Phone-01711525406 [Mail-mmrahman61@gmail.com](mailto:mmrahman61@gmail.com). ORCID Identifier: 0000-0002-4381-1511.

Data availability statement: The data will be within the paper and uploaded as supplementary file.

A funding statement: This research received grant from Director General of Health Services, Government of the peoples' republic of Bangladesh.

Conflict of interest disclosure: The authors declare that there is no conflict of interest.

Ethics approval statement: The Institutional Ethical Committee of Dhaka Medical College approved the study (ERC-DMC/ECC/2021/55).

Patient consent statement: As we mainly reviewed hospital data, there was no scope for written consent. We took verbal permission from the patient for post-covid follow-up.

Permission to reproduce material from other sources: Not applicable

Clinical trial registration: Not applicable

Corresponding Author:

Dr. Reaz Mahmud,

Assistant Professor, Department of Neurology, Dhaka Medical College. Dhaka, Bangladesh.

Phone-+8801912270803.

E-mail-reazdmc22@yahoo.com. rmahmudneuro@dmc.gov.bd.

ORCID ID-0000-0002-9427-1746

Difference in presentation, outcomes, and hospital epidemiologic trend of COVID-19 among first, second, and third waves in Dhaka Medical College

Abstract:

Background

This study aimed to examine the differences in epidemiologic and disease aspects among patients with COVID-19

Methods:

We reviewed the hospital records between April 2020 and September 2021 and followed up on the patients for post-COVID complications.

Findings:

Older adult patients were predominantly affected during the first and second waves, followed by middle-aged patients. Men were predominantly admitted, considering the three waves; although more women were admitted in the second wave. Cough was more common in the second and third waves than in the first wave 522 (59.7%). Respiratory distress was the most common in the third wave, 251(67.1%), and least common in the first wave 403 (46.1%). Anosmia was more common in the third wave 116 (31.2%). In the third wave, patients presenting in a critical state 23 (6.2%) and severe disease 152 (40.8%) were more common. The hospital admission median (IQR) was longer in the first wave, 12 (8–20), than in other waves. More patients were admitted in the first wave (52%) than in the other waves, and patients received more oxygen in the third wave (75%) than in the other waves. Death occurred more commonly in the first wave (51%) than in the other waves. Patients were investigated more commonly in the first and third waves

than in the second wave. The positivity rate was high in the third wave (22.8%) than in other waves. In the third wave, the positivity rate was higher in women (24.3%) than in men. Post-covid cough increased in the second wave and fatigue was higher in the third wave than in other waves. Tiredness and memory loss was greater during the second wave than in other waves.

Conclusion:

This study revealed that the presenting symptoms, outcomes, and epidemiologic trends differed during the COVID-19 waves.

Introduction

On December 31 World Health Organization (WHO) formally reported a case of atypical pneumonia in Wuhan City, China [1], which was later named coronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [2]. On March 11, 2020, WHO declared the novel coronavirus (COVID-19) outbreak a global pandemic [3].

The WHO classified the phases of the pandemic as phases 1–3(predominantly animal infection, few human infections), phase 4(sustained human-to-human infection), phases 5 and 6 (widespread human infection), post-peak (possibility of recurrent events), and post-pandemic (disease activity at seasonal level) [4]. Most of the worst pandemics lasted for several years [5]. After studying the transmission dynamics of SARS-CoV-2, researchers postulated that it would reach long-term circulation within the next five years [6]. Experience in the last 2 years has revealed that resurgence as “waves” is common [4], and the overall pattern of the coronavirus pandemic has been a series of increased COVID-19 waves: which gradually declines. Several outbreaks of illnesses have occurred in various parts of the world. Europe entered its third phase in March 2021 [7], and the United States is likely to experience the 4th wave [8]. The reason for

the seasonal variation in transmission, duration of immunity, degree of cross-immunity between SARS-CoV-2 and other coronaviruses, intensity and timing of control measures [7], and not the least viral mutation can all explain the wave and gradual decline of cases (waves of the disease). [10]. SARS-CoV-2 has mutated at a pace of about 1–2 mutations per month throughout the current global crisis [11]. A variant of SARS-CoV-2 with the *D614G* mutation emerged in China in late January and early February 2020 and immediately became the dominant form of the virus circulating globally [10]. Subsequently, several mutations were recognized as mutations of concern, naming the UK variant known as 501Y. V1, VOC 202012/01, and B.1.1.7, a South African variant known as the 501Y. V2, or B.1.351, a Brazilian variant known as 501Y. V3 or P.1 lineage [11, 12, 13], and the Indian variant B.1.617 (double mutant) [14]. The Indian variant gave rise to India's second wave and stressed its health system. In terms of test positivity rates (TPRs) and case fatality rates (CFRs), the epidemiologic characteristics seem to differ from those of the first wave [15]. Bangladesh reported the peak of the second wave in late February 2021 and the third wave in June 2021 [16]. In the second wave, death rate increased among the young [17]. The African variant was responsible for more than 80% of the second wave, while the delta variant was responsible for 78% of the third wave [17,18]. Preliminary reports of various SARS-CoV-2 mutant strains show transmissibility, severity, and case mortality diversity. The initial study about the African variant reported no significant correlation between severe disease and outcomes. However, higher transmissibility is possible. The mutant virus behavior in Bangladeshi populations remains largely unknown.

Therefore, this study aimed to systematically and scientifically observe the difference in the presentation and outcome of patients with COVID-19 between the first, second, and third waves.

Additionally, we examined the positivity rate, hospital admission rate, and death rate in outpatient department patients.

Materials and Methods

This study aimed to examine differences in the epidemiology of COVID-19 in the first, second, and third waves. We aimed to find if there were any variations in the symptoms, disease severity, case fatality, length of hospital stay, frequency of patients requiring oxygen therapy, and referrals to the intensive care unit (ICU). We reviewed the outpatient data for clinic attendance, hospital admission rate, and death in the outpatient department. We examined the virology laboratory data to observe differences in the positivity rate, number of tests, and age and sex. We reviewed inpatient hospital data for rates of hospital admission and death. We found differences in complications of COVID-19 in patients followed up for at least 6 months after hospital discharge during the first, second, and third waves of COVID-19.

Study area and period

The study was conducted at Dhaka Medical College Hospital between January 01, 2021, and June 20, 2022.

Study design

We conducted a cross-sectional study and a review of the hospital records. We reviewed the hospital records of outpatients, inpatients, and virology departments. We examined the patients' medical. Some patients were followed up for at least 6 months after discharge for post-COVID-19 complications. The telephone interviews followed pre-specified telephone interview guidelines.

Source population

The Dhaka Medical College Hospital inpatient were the source population.

Study population

The study population included inpatients and patients who called back at least 6 months after follow-up.

Eligibility criteria

The study included patients' records, containing important demographics such as age, sex, area of residence, telephone number, complete treatment sheet, admission and discharge date, and at least a brief history. Patients more than 18 years of age, with RT-PCR positive test results irrespective of the severity of the disease admitted between April 2020 and September 2022 were included in this study for analysis and follow-up.

Sample size determination

The sample size was calculated using the formula below, and the hypothesis was that there was no variation in presentation between the COVID-19 waves in Bangladesh during the pandemic:

$$n = \frac{[Z_{\alpha}\sqrt{2p(1-p)} + Z_{\beta}\sqrt{p_1(1-p_1) + p_2(1-p_2)}]^2}{(p_1 - p_2)^2}$$

Here, $Z_{\alpha}=1.96$ Z value of standard normal distribution at 95% confidence interval, P_1 =prevalence of severe infection in the first wave, P_2 =Prevalence of severe disease in the second wave, $RR=1.5$ [risk ratio], $P_2=0.12$; in one study in Bangladesh, the prevalence of severe infection was 11.5% [19], $P_1=RR \times p_2=0.18$, $Z_{\beta}=0.84$ at 80% power, $P=(p_1+p_2) \div 2=0.15$. Thus, the estimated sample size was 240 for each wave.

Sampling technique and procedure

Cluster sampling methods were used. We compiled a list of all wards where patients with COVID-19 had been admitted. We selected one male ward and one female ward. We subsequently reviewed all records that met the inclusion and exclusion criteria. We selected post-COVID follow-up with non-random sampling methods.

Study variables

The variables included in the study were

Demographic variable: Age of the respondents in years and sex

Presenting features of COVID-19: Fever, cough, respiratory distress, sore throat, nausea, vomiting, diarrhea, and body ache.

Investigations in COVID-19 state: Total blood count, CRP, D-dimer, creatinine, and ferritin levels.

COVID-19-severity: COVID-19 positivity, symptoms in case of COVID-19 positivity (asymptomatic, mild, moderate, severe, or critical)

Duration: Duration between symptom onset and hospital admission, length of hospital stay.

Post-COVID-19 conditions: Fatigue, cough, respiratory distress, insomnia, etc.

Outcome-related questions: Discharged and death. Oxygen requirement, ICU referral

Functional impact: We examined functional implications in the post-covid state for at least 6 months for overall functional status, fatigue score, and depression score.

Operational definition: Confirmed Covid-19, and its different severities were defined according to the WHO and National guidelines [19, 20].

Case fatality rate:

$$CFR = \frac{\text{NUMBER OF TOTAL DEATH SURING THE SAME PERIOD IN THE SAME WARD}}{\text{NUMBER OF TOTAL ADMISSION IN THE DEFINED PERIOD IN THE SELECTED WARD}}$$

X100

Duration of hospital stay: The total period from the day of admission to the day of discharge.

Waves of infection: The first, second, and third waves extend between April 2020 to January 2020, February 2021 and May 2021, and June 2021 and September 2021, respectively [21,22].

Post-COVID-19 condition: According to the Center for Disease Control, USA [23]

Post-COVID conditions include a wide range of new, returning, or ongoing health problems that people experience after contracting the SARS-CoV-2 causing COVID-19.

Post-COVID fatigue: The diagnostic criteria for post-COVID-19 fatigue were developed according to the United States Institute of Medicine symptom criteria [24].

The Chalder Fatigue Scale [25], the Karnofsky Performance Status Scale [26], and the depression scale were used to assess fatigue severity, overall functional status, and depression [27].

Data collection instrument

For patients admitted to the hospital, data were collected on a data collection sheet. A telephone directory was used for Post COVID-19 follow-up. We collected data from reports of outpatient, inpatient, and virology departments.

Data Collection procedure

We collected all patients' files from the hospital record unit in the selected ward. Each file was evaluated by one data collector and researcher. The completed data collecting sheet contains a list of all available information. We obtained no specific procedure for missing data and excluded files that did not contain essential information, such as patient demographics,

admission date, and discharge date. We collected the phone number from the hospital records and interviewed the patients for post-covid -19 complications at least 6 months after recovery. We collected data from the outpatient, inpatient, and virology departments using the Excel datasheet, which contains the patient's name, age, sex, date of attendance, outcome, admission, death, discharge, positive or negative status, etc.

Data Quality Control

Each data sheet was reviewed by two researchers; disagreements were resolved through discussion. We removed responses where respondents provided contradictory answers. Because each patient was coded and had a specified hospital record number, there was no scope for double responses.

Data Processing and Analysis

R (v4.1.1) was used to process data. We performed a network analysis with a tidy verse and q graph. Qualitative data with normal distribution were expressed as means (SD), while non-normal data were expressed as medians (IQR). We divided the respondents into groups of first, second, and third waves. We used the chi-square test to calculate quantitative data and one-way ANOVA to calculate quantitative data. A needed we used a post hoc analysis with Bonferroni adjustment, Dunn test, and Tukey's test. We determined epidemiological trends in the EXECL sheet. The p-value for statistical significance was set at <0.05. We did not impute any missing values, and they were included in the analysis.

Ethical consideration

The Institutional Ethical Committee of Dhaka Medical College approved this study (ERC-DMC/ECC/2021/55). As we mainly reviewed the hospital data, there was no need for written consent. The patients provided verbal consent for post-covid follow-up.

Results

We reviewed 1766 patient records and included 1597 patients' data for analysis in this mixed study of retrospective hospital review of hospital data and cross-sectional follow-up of patients admitted for post-COVID-19 complications. From these patients we followed 600 patients over the telephone for post-COVID-19 complications. Between April 2020 and September 2021, and 38578 patients visited the outpatient department, 24501 patients were admitted, 57857 were tested for treatment at the virology department (Suppliment1).

Table 1: Demographic characteristics and co-morbidity of the admitted patients in the three waves

Variable	Categories	Total patient (n=1595) (N)	First wave ^a (n=874) (N) %	Second wave ^b (n=349) (N) %	Third wave ^c (n=372) (N) %	P value
Age (n=1597), mean (SD)		47.91(15.67)	43.82(14.31)	50.79(15.95)	54.62(15.61)	<0.001
	<40 years	512 32.1%	364 41.6%	84 24.1%	64 17.2%	

Age (n= 1595)						<0.001
	40-60 years	652 40.8%	366 41.9%	139 39.8%	147 39.5%	
	60+ years	431 27.02%	144 54.8%	126 36.1%	161 43.3%	
sex (n= 1595)	Female	627 39.31%	283 32.4%	191 54.7%	153 41.0%	<0.001
	Male	968 60.68%	590 67.6%	158 45.3%	220 59.0%	
Fever (n= 1595)	Present	1366 85.6%	738 84.4%	296 85.1%	332 89.0%	0.1
Cough (n= 1595)	Present	1040 65.2%	522 59.7%	228 65.5%	290 78.0%	<0.001
Running nose (n= 1595)	Present	206 12.9%	143 16.4%	16 4.6%	47 12.6%	<0.001
Respiratory distress (n= 1595)	Present	848 (53.1)	403 46.1%	194 55.7%	251 67.1%	<0.001
Sore throat (n= 1595)	Present	278 17.4%	198 22.7%	33 9.5%	47 12.6%	<0.001

Hoarseness of voice (n= 1595)	Present	24 1.5%	11 1.3%	5 1.4%	8 2.1%	0.50
Chest pain (n= 1595)	Present	107 6.7%	52 6.0%	19 5.4%	36 9.6%	0.03
Diarrhea (n= 1595)	Present	152 9.5%	74 8.5%	18 5.2%	60 16.1%	<0.001
Vomiting (n= 1595)	Present	96 6.1%	29 3.3%	8 2.3%	59 15.9%	<0.001
Anorexia (n= 1594)	Present	274 17.1%	123 14.1%	38 11.0%	113 30.2%	<0.001
Anosmia (n= 1593)	Present	301 18.8%	158 18.1%	27 7.8%	116 31.2%	<0.001
Headache (n= 1583)	Present	252 15.7%	145 16.6%	25 7.2%	82 22.5%	<0.001
Lethargy (n= 1597)	Present	436	231 26.4%	106 30.4%	99 26.5%	0.35
Body ache (n= 1596)	Present	286	107 12.2%	87 25.0%	92 24.6%	<0.001
Presenting	Critical ^f	25 1.5%	0 0.0%	2 0.6%	23 6.2%	<0.001
	Mild ^g	747 29.7%	422 48.3%	216 61.9%	109 29.2%	

severity ^d (n= 1595)						
	Moderate ^h	648 40.6%	443 50.7%	116 33.2%	89 23.9%	
	Severe ⁱ	175 10.9%	8 0.9%	15 4.3%	152 40.8%	
Ultimate severity ^e (n= 1595)	Critical ^f	107	32 3.7%	3 0.9%	72 19.3%	<0.001
	Mild ^g	627	365 41.8%	183 52.9%	79 21.1%	
	Moderate ^h	589	383 43.8%	128 37.0%	78 20.9%	
	Severe ⁱ	271	94 10.8%	32 9.2%	145 38.8%	
Diabetes (n= 1151)	Present	531 33.2%	216 28.4%	136 38.8%	179 48.1%	<0.001
Hypertension (n= 1154)	Present	532 33.3	182 24.5%	142 40.6%	208 55.9%	<0.001
Asthma (n= 931)	Present	114 7.1%	57 8.0%	30 8.5%	27 16.0%	<0.001
IHD (n= 930)	Present	123 7.7	29 4.1%	31 8.8%	63 16.9%	<0.001
Renal disease	Present	103 6.4%	24 3.4%	32 9.1%	47 12.6%	<0.001

(n= 926)						
<ul style="list-style-type: none"> a- From April 2020 to January 2020, b- From February 2021 to May 2021 c- From June 2021 to September 2021 d- The severity of the patient at the time of hospital admission e- The severity of the patient in the course of the hospital stays f- Critical: Patient requiring high flow oxygen or mechanical ventilation g- Mild: Patients having mild symptoms of upper respiratory tract viral infection, including mild fever, cough (dry), sore throat, nasal congestion, malaise, headache, muscle pain, anosmia, or malaise; h- Moderate: the patient has respiratory symptoms such as cough and shortness of breath are present without signs of severe pneumonia (tachypnea >30 breaths/min and hypoxia: oxygen saturation <90% on room air). i- Severe: Patients with severe pneumonia require supplemental oxygen through nasal canal, facemask, or face mask with reservoir. 						

276

277

278 The mean age (SD) of the hospital-admitted patients was 47.91(15.67) years, with patients in the
 279 and third waves being higher than those in the first wave ($p < 0.001$). Patients above 60 years
 280 were mainly involved in the first wave 144 (54.8%), the 40–60 age group was primarily involved
 281 in the second wave 139 (39.8%), and those above 60 years were more likely to be infected in the
 282 third wave 161 (43.3%).

283 Men were predominantly admitted 968 (60.68%). However, in the second wave, the number of
 284 women, 191 (54.7%), was higher.

285 Fever was present in 1366 (85.6%) patients and did not differ among the three waves ($p = 0.1$).

286 Cough was more prevalent in the second 288 (65.5%) and third waves 290 (78%) than in the first
 287 wave 522 (59.7%). Running nose was most prevalent in the first wave, 143 (16.4%), and least
 288 prevalent in the second wave, 16 (4.6%). Respiratory distress was the most prevalent in the third
 289 wave, 251 (67.1%), and the least prevalent in the first wave, 403 (46.1%). Sore throat occurred
 290 more prevalent in the first wave 198 (22.7%) than in the other waves. Diarrhea 60 (16.1) and

vomiting 59 (15.9%) were the most prevalent in the third wave. Anosmia was more prevalent in the third wave 116 (31.2%) than in other waves and less frequently in the second wave 27 (7.8%) than in other waves. However, headache was more prevalent in the third 82 (22.5%) and first wave 145 (16.6%) than in the second wave. Body aches occurred more commonly in the second 87 (25%) and third 92 (24.6%) waves than in the first wave. (Table 1)

Patients that presented in a critical condition 23 (6.2%) and severe disease 152 (40.8%) were more prevalent in the third wave than in other waves. In the second wave, most cases were mild 216 (61.9%). During the hospital stay, the severity of the patient's severity changed, and in the third wave, 72 (19.3%) critical and 145 (38.8%) severe diseases emerged. Mild-to-moderate illness was more common in the first and second waves than in the third wave.

Diabetes was more common among admitted patients in the second 136 (38.8%) and third waves 179 (48.1%) than in the first wave. Hypertension was prevalent in the second 142 (40.6%) and third wave 208 (55.9%). Asthma 27 (16%), ischemic heart disease 63 (16.9%), and renal disease 47 (12.6%) were the most prevalent in the third wave (Table 1).

Symptoms Cluster in COVID-19

We found three clusters of symptoms among the admitted COVID patients: 1. Fever, cough, and respiratory distress. 2. Anosmia, headache, and anorexia 3. Sore throat and running nose. The symptom clusters differed for the three waves. In the first wave, we found three clusters; 1. Respiratory distress and cough. 2. Anosmia and anorexia. 3. Running nose and sore throat. In the second wave, we found a cluster of headaches, running nose, sore throat, and hoarseness of voice. In the third wave, we found three clusters: 1. anorexia and anosmia, 2. fever and cough, and 3. headache, diarrhea, and vomiting. (Figure 1)

313 **Figure 1: Symptoms clusters in COVID-19.**

314 **Table 2: Investigation profile of the admitted patients in the three waves**

315

Variable	Total patient (N)	First wave Median (IQR)	Second wave Median (IQR)	Third wave Median (IQR)	P value
WBC	607	8.50 (6.2-11.72)	18.65 (14.55-24.00)	5.95 (1.28-10.23)	<0.001
Neutrophil (%)	595	71.70 (60.92-83.00)	83.00 (79.0-87.0)	78.00 (68.0-86.0)	<0.001
Lymphocyte (%)	595	21.75 (12.88-30.68)	12.00 (10.70-16.0)	18.00 (10.0-27.0)	<0.001
Platelet count	575	247.00 (189.5-324.0)	126.00 (29.9-276.00)	135.00 (31.00-250.00)	<0.001
CRP	438	12.00 (6.0-34.77)	18.00 (8.68-68.50)	39.00 (13.0-85.0)	<0.001
creatinine	547	0.96 (0.80-1.12)	1.180 (0.95-6.62)	1.14 (0.90-1.40)	<0.001
D-dimer	458	0.47 (0.27-1.05)	1.52 (0.62-3.56)	0.79 (0.40-1.80)	<0.001
Ferritin	369	297.00 (122.0-642.0)	1468.00 (973.5-2050.0)	441.00 (235.5-1000.0)	0.002

Serum	191	-	138.00	135.00	0.121
sodium			(135.0-140.8)	(132.0-138.0)	

316

317 The white blood cell count was high in the second wave, 18.65(14.5–24), and low in the third
 318 wave. The platelet count was low in the third wave 78 (68–86). CRP was much higher in the
 319 third wave 39 (13–85) and D-dimer 1.52 (0.63–3.56), and ferritin was high in the second wave
 320 1468 (973–2050). (Table 2)

321 **Table 3: Outcome of the admitted patient in three waves**

322

Variable	Categories	Total patient (N)	First wave (N) %	Second wave (N) %	Third wave (N) %	P value
Ultimate severity	Critical	107	32 29.9%	3 2.8%	72 67.3%	<0.001
	Mild	627	365 58.2%	183 29.2%	79 12.6%	
	Moderate	589	383 65.0%	128 21.7%	78 13.2%	
	Severe	271	94 34.7%	32 11.8%	145 53.5%	
Duration of hospital stay			13.0 (8.0-	12.0 (8.0-12.0)	7.0 (4.0-11.0)	<0.001

			20.0)			
Interval symptom onset and admission			5.0 (4.0-6.0)	5.0 (5.0-6.0)	5.0 (4.0-6.0)	<0.001

323

324 The patient developed a more severe disease in the third wave, and the duration of hospital stay
325 was longer in the first wave 12 (8–20). (Table 3)

326

327 **Table 4: Trend of outpatient, inpatient and virology department consultation in three**
328 **waves**

Trait	Total	First wave	Second wave	Third wave	P value
Outpatient department					
Total Attended	38578	19890 (51.6)	7347 (19.0)	11341 (29.4)	
Positive	5584	3134 (15.7%)	896 (12.1%)	1554 (13.7%)	<0.001
Admitted	25721	13650 (68.6%)	5419 (73.7%)	6652 (58.6%)	<0.001
Death	329	127 (0.6%)	105 (1.4%)	97 (0.8%)	
Admission rate (%)	81.3	80.6	84.4	80.1	
Gender					

Male					
Total Attended	22595	12274 (54.3)	4341 (19.2)	5980 (26.5)	
Positive	3201	1895 (15.4%)	518 (11.9%)	788 (13.1%)	<0.001
Admitted	15133	8541 (69.5%)	3218 (74.1%)	3374 (56.4%)	<0.001
Death	208	86 (0.7%)	64 (1.4%)	58 (0.9%)	
Admission rate (%)	81.6	81.2	84.7	80.0	
Female					
Total Attended	15981	7614 (47.6)	3006 (18.8)	5361 (33.5)	
Positive	2383	1239 (16.2%)	378 (12.5%)	766 (14.2)	<0.001
Admitted	10586	5107 (67%)	2201 (73.2%)	3278 (61.1%)	<0.001
Death	121	41 (0.5%)	41 (1.3%)	39 (0.6%)	
Admission rate (%)	80.9	80.0	84.0	80.3	
Age group					
<40 years					
Total Attended	14264	7297 (51.2)	2354 (16.5)	4613 (32.3)	
Positive	1623	1021 (13.9)	221 (9.3)	381 (8.2)	<0.001
Admitted	6266	3547 (48.6)	1162 (49.3)	1557 (33.7)	<0.001
Death	49	20 (0.2)	13 (0.5)	16 (0.3)	
Admission rate	79.0	77.3	83.2	79.7	

(%)					
40-60 years					
Total Attended	12759	6920 (54.2)	2457 (19.3)	3382 (26.5)	
Positive	2097	1177 (17)	356 (14.4)	564 (16.6)	<0.001
Admitted	9314	5099 (73.6)	1948 (79.2)	2267 (67)	<0.001
Death	121	42 (0.6)	45 (1.8)	34 (1)	
Admission rate (%)	80.8	80.7	82.9	79.1	
60+ years					
Total Attended	11490	5645 (49.1)	2516 (21.9)	3329 (29.0)	
Positive	1852	929 (16.4)	316 (12.5)	607 (18.2)	<0.001
Admitted	10101	4979 (88.2)	2300 (91.4)	2822 (84.7)	<0.001
Death	153	64 (1.1)	47 (1.8)	42 (1.2)	
Admission rate (%)	83.4	83.4	86.4	81.3	
Inpatient consultation					
Trait	Total	First wave N (%)	Second wave N (%)	Third wave N (%)	P value
Total admission	24501	12797 (52.2)	5317 (21.7)	6387 (26.1)	0.0004
Oxygen support	14198	6865 (48.4)	3332 (23.4)	4001 (28.2)	<0.0001
Percentage of		61.8%	69.43%	75.29%	<0.0001

the patient getting oxygen					
ICU admission	4030	3442 (26.8%)	588 (11%)	---	<0.0001
Death	5057	2584 (20%)	1019 (19%)	1454 (22.7%)	<0.0001
Virology department					
Trait	Total	First wave N (%)	Second wave N (%)	Third wave N (%)	P value
Total population					
Total test	57857	26708 (46.1)	13214 (22.8)	17935 (31.0)	
Positive	12870	5962 (46.3)	2814 (21.9)	4094 (31.8)	<0.001
Positivity rate (%)	22.2%	22.3	21.3	22.8	
Gender					
Male					
Total test	32517	15146 (46.6)	7591 (23.3)	9780 (30.1)	
Positive	7082	3416 (48.2)	1553 (21.9)	2113 (29.8)	<0.001
Positivity rate (%)	21.8	22.6	20.5	21.6	
Female					
Total test	25312	11542 (45.6)	5619 (22.2)	8151 (32.2)	
Positive	5782	2542 (44.0)	1260 (21.8)	1980 (34.2)	<0.001

Positivity rate (%)	22.8	22.0	22.4	24.3	
Age group					
<40					
Total test	27055	13408 (49.6)	5291 (19.6)	8356 (30.9)	
Positive	5555	2721 (49.0)	1063 (19.1)	1771 (31.9)	<0.001
Positivity rate (%)	20.5	20.3	20.1	21.2	
40-60					
Total test	13033	6215 (47.7)	2570 (19.7)	4248 (32.6)	
Positive	3148	1538 (48.9)	582 (18.5)	1028 (32.7)	<0.001
Positivity rate (%)	24.2	24.7	22.6	24.2	
>60					
Total test	8210	3477 (42.4)	1678 (20.4)	3055 (37.2)	
Positive	2114	911 (43.1)	369 (17.5)	834 (39.5)	<0.001
Positivity rate (%)	25.7	26.2	22.0	27.3	

329

330 Confirmed COVID-19 cases were higher (15.7%) in the second wave than in the other waves,
331 the admission rate 73.7%, and the death rate 1.4% were higher in the second wave than in other
332 waves. The proportion of confirmed COVID-19 cases was higher among women in all waves. In
333 the third wave, the admission rate among women 61.1% was higher than among men. The

number of positive cases was higher in those below 40 years in the first wave 13.9% and above 60 years in the third wave 18.2%. The admission rate of patients below 40 years was lower in the third wave 33.7%. In the second wave, the admission rate among the 40–60-year age group 79% and above 60 years age group 91.4% was higher than in other waves. In the second wave, the death rate was higher among men 1.4% and women, 1.3% In the second wave, the death rate was high in the 40–60-year age group and above 60-year age group. The admission rate was higher in patients aged above 60 years in all three waves.

52% of patient were admitted in the first wave and 75% received more oxygen in the third wave.

Death was more common 51% in the first wave.

The patient was tested more frequently in the first and third waves than in the second wave. The positivity was high in the third wave 22.8%. In the third wave, the positivity rate was high among women 24.3%. The incidence rate of patients above 60 years was high in the first and third waves 27.3%. (Table 4)

The daily COVID-19 infection rate was higher in the third wave and the duration of the second wave was short. The first wave lasted longer than the other wave, with an elevated and gradual infection rate decline.

The rate of testing was equal for all three waves. The positivity rate was higher during the third than in the first and second waves (Figure 2, Supplement 2).

Figure 2: Epidemiologic trend of number of test positivity, hospital admission and death in three waves

Table 5: post COVID -19 complications of the three waves

Trait	Total patient	First wave	Second wave	Third wave	P value
-------	---------------	------------	-------------	------------	---------

	600	200	200	200	
Age, Mean (SD)	45.2(15.8)	45.5(16.3)	43.6(14.3)	46.5(16.5)	0.19
Sex, Male n (%)	337(56.2)	123(61.5)	97(48.5)	117(58.5)	0.08
Post COVID-19 conditions					
Number of post-covid conditions					0.24
None	40(6.7)	17(8.5)	12(6)	11(5.5)	
Single	93(15.5)	38(19)	30(15.1)	25(12.5)	
Multiple	466(77.7)	145(72.5)	157(78.9)	164(82)	
Symptoms					
Feverish feeling	16(2.7)	6(3)	4(2)	6(3)	0.7
Fatigue	421(70.2)	126(63)	144(72)	151(75.5)	0.03
Cough	127(21.2)	35(17.6)	58(29)	34(17)	0.004
Respiratory distress	40(6.7)	14(7)	15(7.5)	11(5.5)	0.7
Hoarseness of voice	16(2.7)	9(4.5)	2(1)	5(2.5)	0.09
Chest pain	142(23.7)	44(22.1)	40(20.1)	58(29)	0.09
Anorexia	135(22.5)	40(20)	39(19.5)	56(28)	0.07
Anosmia	16(2.7)	7(3.5)	4(2)	5(2.5)	0.6
Headache	146(24.3)	46(23)	49(24.5)	51(25.5)	0.08

Memory disturbance	152(25.4)	46(23)	64(32)	42(21.1)	0.03
Insomnia	73(12.2)	20(10)	29(14.5)	24(11)	0.38
Hypersomnia	4(0.7)	2(1)	2(1)		0.36
Sleep pattern alteration	6(1)	2(1)	2(1)	2(1)	<0.99
Arthralgia	69(11.5)	25(12.6)	28(14)	16(8)	0.15
Confusion	29(4.8)	5(2.5)	12(6)	12(6)	0.18
New onset hypertension	15(2.5)	2(1)	7(3.5)	6(3)	0.23
New onset Diabetes	23(3.8)	8(4)	10(5)	5(2.5)	0.42
Fatigue score, mean (SD)	4.7(2.9)	3.1(2.9)	4.2(3.3)	3.9(3.1)	0.001
Functional status, mean (SD)	90.3(7.4)	90.9(7.7)	90(7.6)	90(6.9)	0.35
Depression	143(25.2)	58(40.6)	49(34.3)	36(25.2)	0.03

356

357 The percentage of patients that developed post-COVID complications was equal in all three
358 waves. However, patients in the second wave developed more post-covid cough and memory
359 disturbance depression, and patients in the third wave developed more fatigue than those in other
360 waves. However, patients in the second wave had increased fatigue scores. The functional status

of the patients was similar in the three waves. We found five symptom clusters. However, they did not differ among the three waves (Figure 3).

Figure 3: Symptom cluster in post COVID-state

Discussion

This study compared the first, second, and third COVID-19 waves in terms of presentation, outcomes, and hospital epidemiological trends. The first wave lasted longer, and however, the second wave lasted for a short period. We found age and sex differences in the admission rates in the three waves. Cough, runny nose, respiratory distress, diarrhea, vomiting, and anosmia were the most common symptom in the three waves. The symptom cluster differed among the three waves. Disease severity, duration of hospital stay, and severity markers differed. We found disparities in the frequencies of the positivity test and death rates. The three waves had similar Post COVID complications.

This study was conducted at the tertiary center of Dhaka. The treatment facility differs from center to center and region to region; therefore, we cannot generalize the findings across the nation and globally.

During replication, a mutation in the genetic code of SARS-CoV-2 leads to the development of a new variant. The behaviors of variants, such as virulence and transmissibility, differ [28]. WHO named the variant to be monitored with the Greek alphabet and named from alpha to zeta [29]. In Bangladesh, until September 2021, alpha, beta, and delta variants were dominant at different times creating, three waves of COVID-19: the first wave was caused by alpha, the second wave

was caused by beta, and the third wave caused by delta variants [18]. Epidemiological and disease characteristics differ in various studies [16,30,31].

In Bangladesh, the first wave lasted approximately 8 months, the second wave approximately 2 months, and the third wave approximately 3 months. This was due to the variations' transmissibility; delta was 63–167% more transmissible than alpha [32]. Therefore, the most susceptible people became infected faster, replacing existing variants. Delta and beta variants spread quickly in Bangladesh, and delta quickly became the dominant variant. Omicron was 2.8 times more transmissible than Delta, thus replacing Delta in a short period [33].

In this study, we found a variation in the demographic patterns across the three variants.

Young people were more affected in the initial wave, as evidenced by the high number of positive cases in the virology laboratory among the young. However, the elderly had a higher positivity rate. The proportion of older adult patients in the hospitalized patients was higher in the first and third waves than in the second wave. The admission rate among the attended patients in the outpatient department was higher in the second wave than in the first and third waves. Because of their increased mobility the younger age group became infected in large numbers. Immune senescence and various comorbidities could explain the older adults' admission. The viral receptors ACE2 and CD26 are more expressed in senescent cells, which explains why older adults are more susceptible to infection [35]. The virus affinity for the receptor varies among the variants. This explains the age group variations among variants [36].

The overall number of admitted men was higher than women. However, the number of women admitted was higher in the second wave. Admission and death rates were higher among men. However,, women had a higher positivity rate than men, especially in the second and third

waves. Men had higher rate of incidence of COVID-19 due to the altered immunologic response, associated comorbidity, hormonal differences, and smoking habits [35]. angiotensin-converting enzyme (ACE) receptor expression is higher in women because its genetic loci are on the X chromosome [37]. The *TMPRSS2* gene is located on chromosome 21q22.3[38]. Some variants have a higher affinity for TMPRSS than for ACE II. This might explain the gender differences in the expression of the various COVID-19 variants. Again, increased testosterone levels may increase the probability of microthrombi formation [39], which is the underlying pathophysiology of severe COVID-19.

The duration of Hospital admission was longer in the first wave, which was most likely due to the severity of the disease at the time of discharge. In the first wave, most patients were admitted because of isolation, and their release was determined by the time of PCR negativity. ICU admission was higher in the first wave due fear an unnecessary patient transfer to the ICU. The death rate was higher in the third wave than in other waves.

The different affinities of the viruses can explain the heterogeneous presentation and clustering of various variants to the receptor. The virus's ability to escape immunity [40] can explain the mutant strain's varied presentation and severity.

The three waves had slightly different post-COVID-19 complications. Further studies on its pathogenesis and immunological response are needed.

Because this was a single-center study, genotyping was either not performed or was impractical for all patients. This was a retrograde study and a review of the documents. Therefore, missing information was likely.

Conclusion

This study revealed that during the COVID-19 waves, the presenting features, outcomes, and epidemiologic trends were different.

Recommendation

In each of the three waves, COVID-19 occurred differently. A mutant strain of the SARS-CoV-2 was most likely the cause of these differences. Therefore, we recommend the following.

1. There should be genetic surveillance for the identification of the specific variant of interest.
2. At the onset of each wave, intensive epidemiologic surveillance should be conducted.
3. There should be diversity in each wave's strategy for disease control planning, treatment, and hospital management.

Acknowledgments

We are grateful to Dhaka Medical College Hospital authority for giving us permission to access the hospital records; without their help it will be impossible to conduct this study.

References:

1. World Health Organization. GCM teleconference – Note for the Records. 10 January 2020. Subject: Pneumonia in Wuhan, China. Available from: [https:// www. who. int/ blueprint / 10-01-2020-nfr-gcm.pdf?ua=](https://www.who.int/blueprint/10-01-2020-nfr-gcm.pdf?ua=).

2. World Health Organization. Novel coronavirus (2019-nCoV). Situation Report – 1. 21 January 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf?sfvrsn=20a99c10_4.
3. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020, available from: <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020>.
4. <https://www.worldometers.info/coronavirus/>, Accessed 25 November 2021.
5. https://www.who.int/influenza/resources/documents/pandemic_phase_descriptions_and_actions.pdf. Accessed 25 November 2021.
6. <https://www.history.com/news/pandemics-end-plague-cholera-black-death-smallpox>. Accessed 25 November 2021
7. Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. **Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period.** *Science* 22 May 2020:Vol. 368, Issue 6493, pp. 860-868. DOI: 10.1126/science.abb5793
8. <https://www.theguardian.com/world/2021/mar/22/lockdowns-return-extended-third-wave-covid-europe>. Accessed 25 November 2021.
9. <https://time.com/5951490/covid-fourth-wave/> Accessed 25 November 2021.
10. <https://www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/>. Accessed 25 November 2021.
11. <https://www.nature.com/articles/d41586-020-02544-6>. Accessed 25 November 2021.
12. <https://www.who.int/csr/don/31-december-2020-sars-cov2-variants/en/>. Accessed 25 November 2021.

13. [European Centre for Disease Prevention and Control 20 Dec 2020 Threat Assessment Brief](#). Accessed 25 November 2021.
14. <https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-emerging-variants.html>. Accessed 19 November 2021.
15. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20210427-weekly-epi-update-37.pdf?sfvrsn=a1ab459c_5&download=true. Accessed 19 November 2021.
16. Ranjan, R., Sharma, A., Verma, M.K., 2021. Characterization of the Second Wave of COVID-19 in India. medRxiv 2021.04.17.21255665. doi: 10.1101/2021.04.17.21255665
17. <https://www.tbsnews.net/coronavirus-chronicle/covid-19-bangladesh/covid-deaths-drop-41-lowest-39-days-242425>. Accessed 19 November 2021.
18. <https://www.icddrb.org/news-and-events/icddrb-in-the-news>. Accessed 19 November 2021.
19. WHO guidance on management of severe acute respiratory infection (SARI) when COVID19 is suspected. Accessed November 1, 2020. [//www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-\(ncov\)-infection-is-suspected](https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected).
20. National Guidelines on Clinical Management of Coronavirus Disease 2019 (COVID-19). 27 May, 2020. Accessed November 1, 2020. <https://dghs.gov.bd/images/docs/Guideline/COVID.Guideline.pdf>.
21. Bari R and Sultana F (2021) Second Wave of COVID-19 in Bangladesh: An Integrated and Coordinated Set of Actions Is Crucial to Tackle Current Upsurge of Cases and Deaths. Front. Public Health 9:699918. doi: 10.3389/fpubh.2021.699918

22. Devnath P, Hossain MJ, Emran TB, Mitra S. Massive third wave of COVID-19 outbreak in Bangladesh: a co-epidemic of dengue might worsen the situation. *Future Virol.* 2022 Jan;10.2217/fvl-2021-0182. doi: 10.2217/fvl-2021-0182. Epub 2022 Mar 8. PMID: 35284001; PMCID: PMC8906578.
23. Post-COVID conditions. Centers for disease control and prevention, USA. Accessed 19 July 2021. From <https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html>
24. Committee on the Diagnostic Criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; Board on the Health of Select Populations; Institute of Medicine. *Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness.* Washington (DC): National Academies Press (US); 2015 Feb 10. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK274235/> DOI: 10.17226/19012.
25. [Chalder, T.](#); [Berelowitz, G.](#); [Pawlikowska, T.](#); [Watts, L.](#); [Wessely, S.](#); [Wright, D.](#); [Wallace, E. P.](#) (1993). ["Development of a fatigue scale"](#). *Journal of Psychosomatic Research.* **37** (2): 147–153. [ISSN 0022-3999](#). [PMID 8463991](#)
26. Karnofsky D, Burchenal J, The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod C, ed. *Evaluation of Chemotherapeutic Agents.* New York, NY: Columbia University Press; 1949:191–205.
27. Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). The PHQ-9: validity of a brief depression severity measure. *Journal of general internal medicine*, *16*(9), 606–613. <https://doi.org/10.1046/j.1525-1497.2001.016009606.x>

28. Islam S, Islam T, Islam MR. New Coronavirus Variants are Creating More Challenges to Global Healthcare System: A Brief Report on the Current Knowledge. Clin Pathol. 2022 Feb 3;15:2632010X221075584. doi: 10.1177/2632010X221075584. PMID: 35141522; PMCID: PMC8819824.
29. <https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications>. Accessed on 01.11.21
30. S. Iftimie, A. F. López-Azcona, I. Vallverdú et al., “First and second waves of coronavirus disease-19: a comparative study in hospitalized patients in Reus, Spain,” *PLoS One*, vol. 16, no. 3, Article ID e0248029, 2021.
31. Kunno J, Supawattanabodee B, Sumanasrethakul C, Wiriyasivaj B, Kuratong S, Kaewchandee C. Comparison of Different Waves during the COVID-19 Pandemic: Retrospective Descriptive Study in Thailand. Adv Prev Med. 2021 Oct 8; 2021:5807056. doi: 10.1155/2021/5807056. PMID: 34659835; PMCID: PMC8519693.
32. Earnest, R, Uddin, R, Matluk, N, et al. Comparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA. Cell Rep Med. 2022;3(4):100583. <https://doi.org/10.1016/j.xcrm.2022.100583>
33. De La Cruz-Hernández, S., & Álvarez-Contreras, A. (2022). Omicron Variant in Mexico: The Fourth COVID-19 Wave. *Disaster Medicine and Public Health Preparedness*, 1-2. doi:10.1017/dmp.2022.160
34. Monod M, Blenkinsop A, Xi X, Hebert D, Bershan S, Tietze S, Baguelin M, Bradley VC, Chen Y, Coupland H, Filippi S, Ish-Horowicz J, McManus M, Mellan T, Gandy A, Hutchinson M, Unwin HJT, van Elsland SL, Vollmer MAC, Weber S, Zhu H, Bezancon A, Ferguson NM, Mishra S, Flaxman S, Bhatt S, Ratmann O; Imperial College COVID-

- 19 Response Team. Age groups that sustain resurging COVID-19 epidemics in the United States. *Science*. 2021 Mar 26;371(6536):eabe8372. doi: 10.1126/science.abe8372. Epub 2021 Feb 2. PMID: 33531384; PMCID: PMC8101272.
35. Al-Bari MAA, Hossain S, Zahan MK. Exploration of sex-specific and age-dependent COVID-19 fatality rate in Bangladesh population. *World J Radiol*. 2021 Jan 28;13(1):1-18. doi: 10.4329/wjr.v13.i1.1. PMID: 33574990; PMCID: PMC7852349.
36. Han Y, Wang Z, Wei Z, Schapiro I, Li J. Binding affinity and mechanisms of SARS-CoV-2 variants. *Comput Struct Biotechnol J*. 2021; 19:4184-4191. doi: 10.1016/j.csbj.2021.07.026. Epub 2021 Jul 26. PMID: 34336146; PMCID: PMC8312055.
37. Schurz H, Salie M, Tromp G, Hoal EG, Kinnear CJ, Möller M. The X chromosome and sex-specific effects in infectious disease susceptibility. *Hum Genomics*. 2019; **13**:2.
38. Stopsack KH, Mucci LA, Antonarakis ES, Nelson PS, Kantoff PW. *TMPRSS2* and COVID-19: Serendipity or Opportunity for Intervention? *Cancer Discov*. 2020; **10**:779–782.
39. Walker RF, Zakai NA, MacLehose RF, Cowan LT, Adam TJ, Alonso A, Lutsey PL. Association of Testosterone Therapy With Risk of Venous Thromboembolism Among Men With and Without Hypogonadism. *JAMA Intern Med*. 2020; **180**:190–197.
40. Liu H, Wei P, Kappler JW, Marrack P, Zhang G. SARS-CoV-2 Variants of Concern and Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity. *Front Immunol*. 2022 Jan 27; 13:825256. doi: 10.3389/fimmu.2022.825256. PMID: 35154144; PMCID: PMC8828474.

Supporting Information:

1. Supplement 1: Patient selection and distribution of the patient for this cross-sectional study
2. Supplement 2: Difference in daily oxygen support, daily positive cases and daily test variability in three waves

582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603

It is made available under a [CC-BY 4.0 International license](#) .

604

605

606

607




Figure 1


Figure 1: Symptoms clusters in COVID-19

- a. According to general clusters of symptoms, We found three clusters of symptoms among the admitted patients with COVID-19: 1. Fever, cough, and respiratory distress. 2. Anosmia, headache, and anorexia, 3. Sore throat and running nose. b . In the first wave, we found three clusters 1. Respiratory distress and cough, 2. Anosmia anorexia, and 3. Running nose and sore throat. c. In the second wave, we found a cluster headache, running nose, sore throat, and hoarseness of voice. d. In the third wave, we found three clusters 1. Anorexia and anosmia, 2. Fever and cough, and 3. headache, diarrhea, and vomiting.



medRxiv preprint doi: <https://doi.org/10.1101/2022.12.14.22283379>; this version posted December 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

^{It is made available under a [CC-BY 4.0 International license](#)}
We did the network analysis with tidy verse and q graph using R (v4.1.1).

(cov-COVID-19, Fvr-Fever, Cgh-cough, Rnn-Running nose, Rsd-Respiratory distress, Srt-Sore throat, Hrv-Hoarseness of voice, Chp-Chest pain, Drr- Diarrhea, Vmt-vomiting, Anr-Anorexia, Ans: Anosmia, Hdc-Headache, Lth-Lethargy, Ach-Body ache)



a medRxiv preprint doi: <https://doi.org/10.1101/2022.12.14.22283379>; this version posted December 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.



c

Figure 2

Figure 2: Epidemiologic trend of number of test positivity, hospital admission and death in three surges

- a. Test positivity-The first surge remained longer and the second surge was narrowest. The daily number of positive cases was high in the second and third surge.
- b. Daily admission-Number of daily admissions was highest in the initial part of the first wave and third wave
- c. Daily death-Number of daily deaths was highest in the initial part of the first wave and third wave

(The first, second, and third waves extend from April 2020 to January 2020, February 2021 to May 2021, and June 2021 to September 2021, respectively)

medRxiv preprint doi: <https://doi.org/10.1101/2022.12.14.22283379>; this version posted December 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](#).




Figure 3

Figure 3: Symptom cluster in post COVID-state

There were five cluster of symptoms in the post-COVID state, 1-diarrhea and vomiting, 2-fatigue and anorexia, 3-memory loss and insomnia, 4-persistent cough and sputum, 5-sore throat and respiratory distress.

We did the network analysis with tidy verse and q graph using R (v4.1.1). (cov-COVID-19, Ftg-Fatigue, Ptc- persistent cough, Spt-sputum, Rsd-Respiratory distress, Srt-Sore throat, Chp-Chest pain, Drr- Diarrhea, Vmt-vomiting, Anr-Anorexia, Ans: Anosmia, Hdc-Headache, NHT: new onset hypertension, NDM: new onset diabetes, Mmd-Memory disturbance

medRxiv preprint doi: <https://doi.org/10.1101/2022.12.14.22283379>; this version posted December 14, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY 4.0 International license](#) .